147 related articles for article (PubMed ID: 18761891)
1. Introduction of human papillomavirus (HPV) vaccination into national immunisation schedules in Europe: Results of the VENICE 2007 survey.
King LA; Lévy-Bruhl D; O'Flanagan D; Bacci S; Lopalco PL; Kudjawu Y; Salmaso S;
Euro Surveill; 2008 Aug; 13(33):. PubMed ID: 18761891
[TBL] [Abstract][Full Text] [Related]
2. The current state of introduction of HPV vaccination into national immunisation schedules in Europe: results of the VENICE 2008 survey.
Lévy-Bruhl D; Bousquet V; King LA; O'Flanagan D; Bacci S; Lopalco PL; Salmaso S;
Eur J Cancer; 2009 Oct; 45(15):2709-13. PubMed ID: 19695863
[TBL] [Abstract][Full Text] [Related]
3. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey.
Dorleans F; Giambi C; Dematte L; Cotter S; Stefanoff P; Mereckiene J; O'Flanagan D; Lopalco PL; D'Ancona F; Levy-Bruhl D;
Euro Surveill; 2010 Nov; 15(47):. PubMed ID: 21144444
[TBL] [Abstract][Full Text] [Related]
4. The current status of HPV and rotavirus vaccines in national immunisation schedules in the EU--preliminary results of a VENICE survey.
Kudjawu Y; Lévy-Bruhl D; Celentano LP; O'Flanagan D; Salmaso S; Lopalco P; Mullins N; Bacci S;
Euro Surveill; 2007 Apr; 12(4):E070426.1. PubMed ID: 17868608
[No Abstract] [Full Text] [Related]
5. Strengthening national teams of experts to support HPV vaccine introduction in Eastern Mediterranean countries: Lessons learnt and recommendations from an international workshop.
Dochez C; Al Awaidy S; Mohsni E; Fahmy K; Bouskraoui M
Vaccine; 2020 Jan; 38(5):1114-1119. PubMed ID: 31771862
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus vaccine introduction--the first five years.
Markowitz LE; Tsu V; Deeks SL; Cubie H; Wang SA; Vicari AS; Brotherton JM
Vaccine; 2012 Nov; 30 Suppl 5():F139-48. PubMed ID: 23199957
[TBL] [Abstract][Full Text] [Related]
7. Mandatory and recommended vaccination in the EU, Iceland and Norway: results of the VENICE 2010 survey on the ways of implementing national vaccination programmes.
Haverkate M; D'Ancona F; Giambi C; Johansen K; Lopalco PL; Cozza V; Appelgren E;
Euro Surveill; 2012 May; 17(22):. PubMed ID: 22687916
[TBL] [Abstract][Full Text] [Related]
8. Vaccine programme stakeholder perspectives on a hypothetical single-dose human papillomavirus (HPV) vaccine schedule in low and middle-income countries.
Gallagher KE; Kelly H; Cocks N; Dixon S; Mounier-Jack S; Howard N; Watson-Jones D
Papillomavirus Res; 2018 Dec; 6():33-40. PubMed ID: 30352297
[TBL] [Abstract][Full Text] [Related]
9. Implementation of a national school-based Human Papillomavirus (HPV) vaccine campaign in Fiji: knowledge, vaccine acceptability and information needs of parents.
La Vincente SF; Mielnik D; Jenkins K; Bingwor F; Volavola L; Marshall H; Druavesi P; Russell FM; Lokuge K; Mulholland EK
BMC Public Health; 2015 Dec; 15():1257. PubMed ID: 26684658
[TBL] [Abstract][Full Text] [Related]
10. Introduction of human papillomavirus (HPV) vaccination in Sweden.
Tegnell A; Dillner J; Andrae B
Euro Surveill; 2009 Feb; 14(6):. PubMed ID: 19215721
[TBL] [Abstract][Full Text] [Related]
11. Options for design of real-world impact studies of single-dose vaccine schedules.
Franceschi S; Clifford GM; Baussano I
Vaccine; 2018 Aug; 36(32 Pt A):4816-4822. PubMed ID: 29571973
[TBL] [Abstract][Full Text] [Related]
12. Organization and quality of HPV vaccination programs in Europe.
Elfström KM; Dillner J; Arnheim-Dahlström L
Vaccine; 2015 Mar; 33(14):1673-81. PubMed ID: 25720792
[TBL] [Abstract][Full Text] [Related]
13. Psychosocial determinants of parental human papillomavirus (HPV) vaccine decision-making for sons: Methodological challenges and initial results of a pan-Canadian longitudinal study.
Perez S; Tatar O; Shapiro GK; Dubé E; Ogilvie G; Guichon J; Gilca V; Rosberger Z
BMC Public Health; 2016 Dec; 16(1):1223. PubMed ID: 27919239
[TBL] [Abstract][Full Text] [Related]
14. Coverage of human papillomavirus vaccination during the first year of its introduction in Spain.
Limia A; Pachón I
Euro Surveill; 2011 May; 16(21):. PubMed ID: 21632017
[TBL] [Abstract][Full Text] [Related]
15. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis.
Donken R; Knol MJ; Bogaards JA; van der Klis FR; Meijer CJ; de Melker HE
J Infect; 2015 Jul; 71(1):61-73. PubMed ID: 25709084
[TBL] [Abstract][Full Text] [Related]
16. Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009-2014.
Ladner J; Besson MH; Audureau E; Rodrigues M; Saba J
BMC Health Serv Res; 2016 Oct; 16(1):575. PubMed ID: 27737666
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs.
Markowitz LE; Drolet M; Perez N; Jit M; Brisson M
Vaccine; 2018 Aug; 36(32 Pt A):4806-4815. PubMed ID: 29802000
[TBL] [Abstract][Full Text] [Related]
18. Progress toward implementation of human papillomavirus vaccination--the Americas, 2006-2010.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Oct; 60(40):1382-4. PubMed ID: 21993342
[TBL] [Abstract][Full Text] [Related]
19. Key decision-making factors for human papillomavirus (HPV) vaccine program introduction in low-and-middle-income-countries: Global and national stakeholder perspectives.
Guillaume D; Waheed DE; Schlieff M; Muralidharan K; Vorsters A; Limaye R
Hum Vaccin Immunother; 2022 Dec; 18(7):2150454. PubMed ID: 36485172
[TBL] [Abstract][Full Text] [Related]
20. Strengthening vaccination policies in Latin America: an evidence-based approach.
Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
